The Essen-based chemicals group is launching a research cooperation with scientists from the renowned Stanford University in California.
mRNA technology is considered revolutionary. In the future, it will be used not only in the fight against Covid-19, but also in the treatment of diseases such as cancer or AIDS. To explore these potential applications, Essen-based Evonik and Stanford University are launching a three-year research collaboration. "With this project, we are developing the next generation of mRNA-based medicine," says Thomas Riermeier, head of Evonik's Health Care Business Unit.
The Essen-based chemical company specializes in drug delivery technologies, which are needed in mRNA therapies to deliver active ingredients to their site of action in the body in a targeted and safe manner. The research project will help to further develop, license and market this technology. "We are proud to collaborate with Stanford and combine our innovative strengths in advanced drug delivery technology," says Riermeier.
Evonik is a global leader in specialty chemicals. The Group is active in over 100 countries, generating sales of €12.2 billion in 2020.